CIK 0001237831
- Large accelerated filer
GLOBUS MEDICAL INC
Sign in to watch- Ticker
- GMED
- Exchange
- NYSE
- Industry
- Surgical & Medical Instruments & Apparatus
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 043744954
- Phone
- +1 610-930-1800
- Business address
- 2560 GENERAL ARMISTEAD AVENUE, AUDUBON, PA, 19403
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $5,794,049
- in 3 filings, $425K under 10b5-1 plans
Net −$5,794,049. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2020-07-22 | Douglas Robert Andrew Director | Purchase | +690 | $47.75 | $33K | 1,390 |
| 2020-06-22 | Douglas Robert Andrew Director | Purchase | +700 | $48.20 | $34K | 700 |
| 2020-06-11 | Huller Kelly SVP, GC, Corporate Secretary | Exercise or conversion | +9,076 | $11.28 | $102K | 9,076 |
| 2020-06-11 | Huller Kelly SVP, GC, Corporate Secretary | Sale | −9,076 | $51.00 | $463K | 0 |
| 2020-06-11 | Huller Kelly SVP, GC, Corporate Secretary | Exercise or conversion · Stock Option (Right to Buy Class A Common Stock) | −9,076 | 14,000 | ||
| 2020-05-21 | Scavilla Daniel T EVP, Chief Commercial Officer | Exercise or conversion | +31,250 | $25.40 | $794K | 31,250 |
| 2020-05-21 | Scavilla Daniel T EVP, Chief Commercial Officer | Exercise or conversion | +68,750 | $25.52 | $1.8M | 100,000 |
| 2020-05-21 | Scavilla Daniel T EVP, Chief Commercial Officer | Sale | −100,000 | $55.09 | $5.5M | 0 |
| 2020-05-21 | Scavilla Daniel T EVP, Chief Commercial Officer | Exercise or conversion · Stock Option (Right to Buy Class A Common Stock) | −31,250 | 0 | ||
| 2020-05-21 | Scavilla Daniel T EVP, Chief Commercial Officer | Exercise or conversion · Stock Option (Right to Buy Class A Common Stock) | −68,750 | 50,000 | ||
| 2020-01-22 | ZARRILLI STEPHEN T Director | Grant or award · Stock Option (Right to Buy Class A Common Stock) | +25,000 | 25,000 | ||
| 2020-01-22 | TOBIN JAMES R Director | Grant or award · Stock Option (Right to Buy Class A Common Stock) | +25,000 | 25,000 | ||
| 2020-01-22 | Lemaitre Dan Director | Grant or award · Stock Option (Right to Buy Class A Common Stock) | +25,000 | 25,000 | ||
| 2020-01-22 | Davidar David D Director | Grant or award · Stock Option (Right to Buy Class A Common Stock) | +25,000 | 25,000 | ||
| 2020-01-22 | RHOADS ANN D Director | Grant or award · Stock Option (Right to Buy Class A Common Stock) | +25,000 | 25,000 | ||
| 2020-01-22 | Pfeil Keith W SVP, Chief Financial Officer | Grant or award · Stock Option (Right to Buy Class A Common Stock) | +40,000 | 40,000 | ||
| 2020-01-22 | Huller Kelly SVP, GC, Corporate Secretary | Grant or award · Stock Option (Right to Buy Class A Common Stock) | +40,000 | 40,000 | ||
| 2020-01-22 | Scavilla Daniel T EVP, Chief Commercial Officer | Grant or award · Stock Option (Right to Buy Class A Common Stock) | +80,000 | 80,000 | ||
| 2020-01-22 | Paul David C Executive Chairman | Grant or award · Stock Option (Right to Buy Class A Common Stock) | +100,000 | 100,000 | ||
| 2020-01-22 | Demski David M President, CEO | Grant or award · Stock Option (Right to Buy Class A Common Stock) | +175,000 | 175,000 |
Page 19 of 25 · 498 trades